Aquestive Capital Stock from 2010 to 2025

AQST Stock

USD 3.25 0.04 1.25%

Aquestive Therapeutics Capital Stock yearly trend continues to be comparatively stable with very little volatility. Capital Stock will likely drop to about 55 K in 2025. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

91 K

Current Value

55 K

Quarterly Volatility

19.8 K

Credit Downgrade

Yuan Drop

Covid

Check Aquestive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aquestive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 10.3 M, Selling General Administrative of 44.5 M or Total Revenue of 49.6 M, as well as many indicators such as Price To Sales Ratio of 3.99, Dividend Yield of 0.0 or Days Sales Outstanding of 63.82. Aquestive financial statements analysis is a perfect complement when working with Aquestive Therapeutics Valuation or Volatility modules.

Check out the analysis of Aquestive Therapeutics Correlation against competitors.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

Latest Aquestive Therapeutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Aquestive Therapeutics over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Aquestive Therapeutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aquestive Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Aquestive Capital Stock Regression Statistics

	Arithmetic Mean	37,812
	Geometric Mean	34,220
	Coefficient Of Variation	52.46
	Mean Deviation	15,242
	Median	25,000
	Standard Deviation	19,837
	Sample Variance	393.5M
	Range	66K
	R-Value	0.79
	Mean Square Error	155.5M
	R-Squared	0.63
	Significance	0.0002
	Slope	3,310
	Total Sum of Squares	5.9B

Aquestive Capital Stock History

	2024	91 K
	2023	69 K
	2022	55 K
	2021	41 K
	2020	35 K
	2019	34 K

Other Fundumenentals of Aquestive Therapeutics

Issuance Of Capital Stock

Aquestive Therapeutics Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Good Will
Total Assets		-0.27	0.11	-0.56	0.77	0.45	0.15	0.66	-0.56	1.0	-0.5	-0.15	-0.8	-0.44	0.1	-0.77	-0.83	0.73	-0.36	0.69	-0.36	0.75	0.62	-0.36
Total Stockholder Equity	-0.27		0.59	0.88	-0.01	0.05	0.09	-0.9	0.35	-0.22	0.31	-0.35	0.58	0.61	-0.72	0.16	0.36	-0.77	0.23	0.3	0.23	-0.05	-0.72	0.23
Net Tangible Assets	0.11	0.59		0.55	0.27	-0.04	-0.25	-0.4	-0.44	0.18	-0.35	-0.03	-0.16	-0.17	-0.55	-0.11	-0.29	-0.12	0.22	0.73	0.22	0.18	-0.37	0.22
Retained Earnings	-0.56	0.88	0.55		-0.17	-0.08	0.0	-0.9	0.48	-0.52	0.41	-0.27	0.69	0.63	-0.62	0.56	0.54	-0.83	0.6	0.08	0.6	-0.49	-0.9	0.6
Accounts Payable	0.77	-0.01	0.27	-0.17		0.52	0.09	0.35	-0.28	0.78	-0.34	-0.29	-0.57	-0.08	0.1	-0.54	-0.71	0.39	-0.11	0.74	-0.11	0.46	0.18	-0.11
Long Term Debt	0.45	0.05	-0.04	-0.08	0.52		0.75	0.16	0.16	0.43	0.06	-0.8	-0.21	0.17	-0.16	-0.05	-0.16	0.16	-0.01	0.5	-0.01	0.25	-0.14	-0.01
Net Receivables	0.15	0.09	-0.25	0.0	0.09	0.75		0.01	0.34	0.12	0.49	-0.73	0.07	0.4	-0.33	0.17	0.11	-0.12	0.12	0.12	0.12	0.05	-0.16	0.12
Total Liab	0.66	-0.9	-0.4	-0.9	0.35	0.16	0.01		-0.5	0.62	-0.45	0.21	-0.8	-0.66	0.6	-0.42	-0.63	0.93	-0.26	0.07	-0.26	0.32	0.83	-0.26
Short Long Term Debt	-0.56	0.35	-0.44	0.48	-0.28	0.16	0.34	-0.5		-0.59	0.82	-0.38	0.84	0.89	-0.1	0.63	0.81	-0.71	0.37	-0.51	0.37	-0.62	-0.58	0.37
Total Current Assets	1.0	-0.22	0.18	-0.52	0.78	0.43	0.12	0.62	-0.59		-0.53	-0.11	-0.8	-0.45	0.08	-0.78	-0.83	0.72	-0.36	0.73	-0.36	0.77	0.61	-0.36
Short Term Debt	-0.5	0.31	-0.35	0.41	-0.34	0.06	0.49	-0.45	0.82	-0.53		-0.31	0.68	0.82	-0.34	0.56	0.59	-0.72	0.33	-0.44	0.33	-0.55	-0.5	0.33
Intangible Assets	-0.15	-0.35	-0.03	-0.27	-0.29	-0.8	-0.73	0.21	-0.38	-0.11	-0.31		-0.12	-0.43	0.53	-0.11	-0.08	0.23	-0.14	-0.36	-0.14	-0.03	0.49	-0.14
Common Stock	-0.8	0.58	-0.16	0.69	-0.57	-0.21	0.07	-0.8	0.84	-0.8	0.68	-0.12		0.79	-0.26	0.65	0.93	-0.89	0.35	-0.57	0.35	-0.61	-0.66	0.35
Property Plant Equipment	-0.44	0.61	-0.17	0.63	-0.08	0.17	0.4	-0.66	0.89	-0.45	0.82	-0.43	0.79		-0.29	0.45	0.64	-0.83	0.34	-0.25	0.34	-0.44	-0.65	0.34
Current Deferred Revenue	0.1	-0.72	-0.55	-0.62	0.1	-0.16	-0.33	0.6	-0.1	0.08	-0.34	0.53	-0.26	-0.29		-0.13	-0.1	0.51	-0.2	-0.38	-0.2	-0.02	0.58	-0.2
Net Debt	-0.77	0.16	-0.11	0.56	-0.54	-0.05	0.17	-0.42	0.63	-0.78	0.56	-0.11	0.65	0.45	-0.13		0.76	-0.52	0.78	-0.5	0.78	-0.93	-0.66	0.78
Long Term Debt Total	-0.83	0.36	-0.29	0.54	-0.71	-0.16	0.11	-0.63	0.81	-0.83	0.59	-0.08	0.93	0.64	-0.1	0.76		-0.71	0.4	-0.67	0.4	-0.68	-0.57	0.4
Capital Surpluse	0.73	-0.77	-0.12	-0.83	0.39	0.16	-0.12	0.93	-0.71	0.72	-0.72	0.23	-0.89	-0.83	0.51	-0.52	-0.71		-0.3	0.29	-0.3	0.48	0.81	-0.3
Deferred Long Term Liab	-0.36	0.23	0.22	0.6	-0.11	-0.01	0.12	-0.26	0.37	-0.36	0.33	-0.14	0.35	0.34	-0.2	0.78	0.4	-0.3		-0.09	1.0	-0.79	-0.54	1.0
Net Invested Capital	0.69	0.3	0.73	0.08	0.74	0.5	0.12	0.07	-0.51	0.73	-0.44	-0.36	-0.57	-0.25	-0.38	-0.5	-0.67	0.29	-0.09		-0.09	0.59	-0.02	-0.09
Long Term Investments	-0.36	0.23	0.22	0.6	-0.11	-0.01	0.12	-0.26	0.37	-0.36	0.33	-0.14	0.35	0.34	-0.2	0.78	0.4	-0.3	1.0	-0.09		-0.79	-0.54	1.0
Net Working Capital	0.75	-0.05	0.18	-0.49	0.46	0.25	0.05	0.32	-0.62	0.77	-0.55	-0.03	-0.61	-0.44	-0.02	-0.93	-0.68	0.48	-0.79	0.59	-0.79		0.57	-0.79
Capital Stock	0.62	-0.72	-0.37	-0.9	0.18	-0.14	-0.16	0.83	-0.58	0.61	-0.5	0.49	-0.66	-0.65	0.58	-0.66	-0.57	0.81	-0.54	-0.02	-0.54	0.57		-0.54
Good Will	-0.36	0.23	0.22	0.6	-0.11	-0.01	0.12	-0.26	0.37	-0.36	0.33	-0.14	0.35	0.34	-0.2	0.78	0.4	-0.3	1.0	-0.09	1.0	-0.79	-0.54

Click cells to compare fundamentals

About Aquestive Therapeutics Financial Statements

Aquestive Therapeutics shareholders use historical fundamental indicators, such as Capital Stock, to determine how well the company is positioned to perform in the future. Although Aquestive Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aquestive Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aquestive Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Capital Stock	91 K	55 K
Issuance Of Capital Stock	83.8 M	87.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aquestive Capital Stock from 2010 to 2025

Latest Aquestive Therapeutics' Capital Stock Growth Pattern

Aquestive Capital Stock Regression Statistics

Aquestive Capital Stock History

Other Fundumenentals of Aquestive Therapeutics

Aquestive Therapeutics Capital Stock component correlations

About Aquestive Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aquestive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY